×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Glaucoma Surgery Market

ID: MRFR/MED/17433-HCR
100 Pages
Garvit Vyas
October 2025

US Glaucoma Surgery Market Research Report By Target (Trabecular meshwork, Suprachoroidal space, Others), By Type of surgery (Angle closure glaucoma surgery, Aqueous shunt surgery, laser surgery, Others) and By End User (Hospital, Ambulatory surgery centers, Others) - Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Glaucoma Surgery Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

US Glaucoma Surgery Market Summary

As per analysis, the US glaucoma surgery market is projected to grow from USD 178.67 Million in 2024 to USD 365.4 Million by 2035, exhibiting a compound annual growth rate (CAGR) of 6.72% during the forecast period (2025 - 2035).

Key Market Trends & Highlights

The US glaucoma surgery market is experiencing a shift towards minimally invasive techniques and advanced surgical options.

  • Trabeculectomy remains the largest segment in the US glaucoma surgery market, driven by its established efficacy.
  • Minimally invasive glaucoma surgery is the fastest-growing segment, reflecting a trend towards less invasive treatment options.
  • Technological advancements and regulatory support for new therapies are shaping the market landscape.
  • The increasing prevalence of glaucoma and rising healthcare expenditure are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size 178.67 (USD Million)
2035 Market Size 365.4 (USD Million)
CAGR (2025 - 2035) 6.72%

Major Players

Alcon (US), AbbVie (US), Johnson & Johnson (US), Bausch Health (US), Glaukos Corporation (US), Santen Pharmaceutical (US), Carl Zeiss AG (DE), Merck & Co. (US), Novartis (CH)

US Glaucoma Surgery Market Trends

The US glaucoma surgery market is currently experiencing a notable evolution, driven by advancements in surgical techniques and technologies. As the prevalence of glaucoma continues to rise, there is an increasing demand for effective treatment options. Surgeons are adopting minimally invasive procedures, which tend to offer quicker recovery times and reduced complications. This shift not only enhances patient outcomes but also aligns with the broader trend towards personalized medicine, where treatments are tailored to individual patient needs. Furthermore, the integration of innovative devices and surgical instruments is likely to enhance the precision and efficacy of glaucoma surgeries, thereby improving overall patient satisfaction. In addition to technological advancements, the regulatory landscape in the US is evolving to support the introduction of new therapies and surgical options. Regulatory bodies are streamlining approval processes for novel devices, which may facilitate quicker access to cutting-edge treatments for patients. Moreover, educational initiatives aimed at both healthcare providers and patients are becoming increasingly prevalent, fostering a better understanding of glaucoma management. This growing awareness is expected to drive demand for surgical interventions, as more individuals seek proactive solutions to manage their condition. Overall, the US glaucoma surgery market appears poised for continued growth, characterized by innovation and a patient-centered approach.

Minimally Invasive Techniques

The US glaucoma surgery market is witnessing a shift towards minimally invasive surgical techniques. These procedures, which often involve smaller incisions and reduced tissue trauma, are gaining traction due to their potential for quicker recovery and fewer complications. Surgeons are increasingly adopting these methods, which may lead to improved patient outcomes and satisfaction.

Technological Advancements

Innovations in surgical devices and technologies are playing a crucial role in shaping the US glaucoma surgery market. The introduction of advanced instruments and techniques enhances the precision of surgeries, potentially leading to better management of glaucoma. This trend suggests a growing emphasis on integrating technology into clinical practice.

Regulatory Support for New Therapies

The regulatory environment in the US is evolving to facilitate the introduction of new surgical options and therapies for glaucoma. Streamlined approval processes for innovative devices may enhance patient access to cutting-edge treatments. This trend indicates a supportive framework for advancements in glaucoma management.

Market Segment Insights

By Surgery Type: Trabeculectomy (Largest) vs. Minimally Invasive Glaucoma Surgery (Fastest-Growing)

In the US glaucoma surgery market, trabeculectomy remains the largest segment, largely due to its long-standing history as a reliable surgical intervention for managing glaucoma. A significant portion of patients opting for surgical procedures still choose trabeculectomy due to its effectiveness and established outcomes. Conversely, minimally invasive glaucoma surgery (MIGS) is rapidly gaining traction, representing the fastest-growing segment in recent years as it offers reduced recovery times and lower complication rates, appealing to both patients and surgeons. The growth of minimally invasive options is being driven by advancements in surgical technology and increasing awareness among patients and physicians. With a market that is increasingly favoring administrative changes and innovative solutions, MIGS offers a promising alternative that meets the demands of a more patient-centric healthcare model. These shifts are indicative of evolving trends, with a noticeable preference trending towards less invasive procedures, reflecting broad changes in patient outcomes and satisfaction.

Trabeculectomy (Dominant) vs. Tube Shunt Surgery (Emerging)

Trabeculectomy holds a dominant position in the US glaucoma surgery market, recognized for its effectiveness in controlling intraocular pressure and providing lasting results. Although considered the gold standard, it is also associated with various risks and complications, which can lead some patients to explore alternatives. Tube shunt surgery, classified as an emerging segment, serves as a viable option particularly for patients who may not be suitable candidates for trabeculectomy. This approach minimizes the risk of complications often associated with traditional surgery and is seeing increased adoption due to its effectiveness in managing refractory glaucoma cases. Tube shunt surgeries are benefitting from improvements in techniques and technologies that enhance outcomes and reduce recovery times, positioning them favorably alongside trabeculectomy in clinical settings.

By Procedure Type: Invasive Surgery (Largest) vs. Non-Invasive Surgery (Fastest-Growing)

In the US glaucoma surgery market, the distribution of procedure types reveals a significant dominance of invasive surgeries. This approach encompasses traditional techniques, which have established themselves as the foundational treatment method for severe glaucoma cases. Meanwhile, non-invasive surgeries, though currently smaller in market share, have been rapidly gaining traction among practitioners and patients due to lower risk profiles and quicker recovery times. Combined surgeries also play a crucial role, but they tend to be performed in conjunction with other procedures rather than as stand-alone treatments, thus influencing overall market dynamics. Despite the current standing of invasive surgery as the largest segment, non-invasive surgery is emerging as a strong contender, driven by technological advancements and patient preference for minimally invasive options. Factors such as increased awareness about glaucoma, improved surgical devices, and the growing aging population contribute to the heightened interest in non-invasive techniques. As healthcare evolves, the emphasis on safety and rapid recovery fuels this segment's expansion, suggesting an exciting shift in standard treatment approaches within the market in the coming years.

Invasive Surgery (Dominant) vs. Combined Surgery (Emerging)

Invasive surgery remains the dominant procedure type in the US glaucoma surgery market, characterized by techniques that often involve traditional methods such as trabeculectomy or tube shunt surgeries. These procedures have a long history of effectiveness, setting the benchmark for managing advanced glaucoma cases. Conversely, combined surgery, which merges glaucoma treatments with cataract surgery, is an emerging focus area. This approach not only addresses dual issues that patients commonly face but also enhances surgical outcomes. The synergy of treating both conditions during a single procedure appeals to a growing patient demographic, leading to its rise in popularity. Thus, while invasive surgery maintains its established influence, the dual benefits of combined surgery present valuable opportunities for growth.

By Technology: Laser Technologies (Largest) vs. Micro-Invasive Techniques (Fastest-Growing)

In the US glaucoma surgery market, Laser Technologies currently holds the largest share, reflecting its established role and acceptance among healthcare professionals and patients alike. Conventional Techniques also command a significant portion of the market; however, their position is gradually diminishing as newer technologies gain traction. Micro-Invasive Techniques are increasingly capturing attention, particularly due to their minimally invasive nature and reduced recovery times, indicating a transformative shift in surgical preferences. Growth trends in the US glaucoma surgery market are driven by technological advancements, increasing awareness of glaucoma management, and an aging population that demands effective treatment options. As practitioners seek less invasive solutions with quicker recovery, Micro-Invasive Techniques are expected to see substantial growth, positioning themselves as an essential component of modern glaucoma treatment. The robustness of Laser Technologies serves as a testament to the ongoing evolution within this market segment, blending innovation with patient-centered care.

Laser Technologies: Dominant vs. Micro-Invasive Techniques: Emerging

The dominance of Laser Technologies in the US glaucoma surgery market stems from their efficacy and precision in treating various forms of glaucoma, thereby minimizing complications and improving patient outcomes. They provide a blend of therapeutic benefits that appeal to both surgeons and patients. On the other hand, Micro-Invasive Techniques are emerging rapidly within the market landscape, offering groundbreaking solutions that combine surgical intervention with the advantages of a minimally invasive approach. This approach ensures less trauma and faster healing, making it particularly appealing to patients with lifestyle considerations. The dynamic interplay between these two segment values illustrates a critical shift towards innovative treatment paradigms that prioritize safety and efficacy.

By Patient Demographics: Aging Population (Largest) vs. Women (Fastest-Growing)

In the US glaucoma surgery market, the patient demographics significantly influence market dynamics. The aging population represents the largest segment, with a substantial proportion of glaucoma cases occurring in older adults. Additionally, the gender distribution shows that women are increasingly seeking glaucoma treatment, making up a growing percentage of the patient base in recent years. This evolving demographic landscape underscores the need for tailored treatment solutions that cater to these specific groups. As the population ages, there is a notable increase in awareness and screening for glaucoma, particularly in women, who often seek medical treatment later than men. Since glaucoma can lead to severe vision impairment, the growing prevalence among older adults combined with heightened awareness in women drives demand for innovative surgical interventions. Moreover, outreach programs targeting these demographics are likely to further boost market growth.

Age Group (Dominant) vs. Gender (Emerging)

The aging population forms the dominant demographic segment in the US glaucoma surgery market, given the higher incidence rates of glaucoma among elderly patients. This group often presents with advanced stages of the disease, requiring more complex surgical interventions. Conversely, the female demographic is an emerging segment, experiencing an increase in glaucoma diagnoses and surgeries due to rising awareness and health-seeking behaviors among women. Factors such as hormonal changes during menopause, which can impact ocular health, are prompting more women to seek preventive care and treatment. The industry is witnessing a shift in marketing strategies to address the specific needs of female patients, alongside the comprehensive care options available for the aging population.

By Post-Operative Care: Medication Management (Largest) vs. Prescription Follow-Ups (Fastest-Growing)

In the US glaucoma surgery market, the post-operative care segment is primarily comprised of Medication Management, Follow-Up Procedures, and Rehabilitation Services. Medication Management holds the largest share, as it ensures patients receive the necessary medications to prevent complications and manage intraocular pressure effectively. Follow-Up Procedures and Rehabilitation Services play crucial roles in assessing surgical outcomes and restoring patient functionality but occupy smaller portions of the market relative to Medication Management.

Medication Management (Dominant) vs. Follow-Up Procedures (Emerging)

Medication Management is a pivotal component of the post-operative care in glaucoma surgery, responsible for prescribing and monitoring medications to maintain optimal eye health and prevent disease progression. It encompasses a range of treatments, including eye drops and oral medications, tailored to individual patient needs. In contrast, Follow-Up Procedures, though emerging, are gaining traction as patients increasingly recognize the importance of consistent monitoring post-surgery. These procedures typically include routine eye examinations and imaging techniques to evaluate surgical success and adjust treatment plans. Together, these services enhance patient outcomes and satisfaction in the glaucoma management continuum.

Get more detailed insights about US Glaucoma Surgery Market
Request Free Sample

Key Players and Competitive Insights

The glaucoma surgery market is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing prevalence of glaucoma among the aging population. Key players such as Alcon (US), Glaukos Corporation (US), and AbbVie (US) are strategically positioned to leverage innovation and expand their market presence. Alcon (US) focuses on enhancing its surgical portfolio through cutting-edge technologies, while Glaukos Corporation (US) emphasizes its commitment to minimally invasive surgical techniques. AbbVie (US), on the other hand, is actively pursuing strategic partnerships to bolster its product offerings, thereby shaping a competitive environment that prioritizes innovation and patient-centric solutions.

In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Johnson & Johnson (US) and Bausch Health (US) suggests a trend towards consolidation, as these firms seek to strengthen their competitive positions through mergers and acquisitions.

In November 2025, Alcon (US) announced the launch of its latest surgical device designed to improve outcomes in glaucoma procedures. This strategic move is significant as it underscores Alcon's commitment to innovation and its aim to capture a larger share of the market by offering advanced solutions that address unmet clinical needs. The introduction of this device is likely to enhance surgical precision and patient recovery times, thereby reinforcing Alcon's competitive edge.

In October 2025, Glaukos Corporation (US) entered into a collaboration with a leading technology firm to integrate artificial intelligence (AI) into its surgical platforms. This partnership is pivotal, as it positions Glaukos at the forefront of digital transformation in glaucoma surgery. By harnessing AI, the company aims to improve surgical outcomes and streamline operational processes, which could potentially redefine standards in the industry.

In September 2025, AbbVie (US) completed the acquisition of a smaller biotech firm specializing in novel glaucoma therapies. This acquisition is strategically important as it expands AbbVie's product pipeline and enhances its capabilities in addressing complex glaucoma cases. The integration of these innovative therapies into AbbVie's portfolio may provide a competitive advantage in a market that increasingly values comprehensive treatment options.

As of December 2025, current trends in the glaucoma surgery market indicate a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming increasingly vital, as companies recognize the need to collaborate to enhance their technological capabilities and market reach. Looking ahead, competitive differentiation is likely to evolve, shifting from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition suggests that companies that prioritize research and development, alongside strategic partnerships, will be better positioned to thrive in an increasingly competitive landscape.

Key Companies in the US Glaucoma Surgery Market market include

Industry Developments

Recent developments in the US Glaucoma Surgery Market have shown significant activity among key players. Companies such as Alcon and Glaukos have advanced their Research and Development initiatives to innovate new surgical techniques and devices aimed at improving patient outcomes.

Aerie Pharmaceuticals has reported growth in its product pipeline, while Novartis continues to expand its therapeutic options for managing glaucoma. In terms of mergers and acquisitions, Santen Pharmaceutical announced the acquisition of a portfolio of assets from a private firm in September 2023, which is expected to bolster its presence in the US market.

Additionally, Bausch Health has made strategic investments to enhance its product offerings, reinforcing its position in the competitive landscape. The heightened focus on minimally invasive surgical options is driving industry growth, as patient demand for less invasive procedures increases.

In the past two years, the industry has witnessed substantial funding allocated towards technological advancements and collaborations among major companies like Johnson and Johnson and Heidelberg Engineering, influencing the market dynamics.

Overall, the US Glaucoma Surgery Market is experiencing a robust expansion, underpinned by continuous innovation and strategic alignments among leading firms.

Future Outlook

US Glaucoma Surgery Market Future Outlook

The US glaucoma surgery market is projected to grow at a 6.72% CAGR from 2024 to 2035, driven by technological advancements, increasing prevalence, and enhanced patient awareness.

New opportunities lie in:

  • Development of minimally invasive surgical techniques for faster recovery
  • Integration of AI-driven diagnostic tools for personalized treatment plans
  • Expansion of telemedicine platforms for remote patient monitoring and consultations

By 2035, the market is expected to be robust, driven by innovation and increased accessibility.

Market Segmentation

US Glaucoma Surgery Market Technology Outlook

  • Conventional Techniques
  • Laser Technologies
  • Micro-Invasive Techniques
  • Robotic Surgery

US Glaucoma Surgery Market Surgery Type Outlook

  • Trabeculectomy
  • Tube Shunt Surgery
  • Minimally Invasive Glaucoma Surgery
  • Laser Surgery

US Glaucoma Surgery Market Procedure Type Outlook

  • Invasive Surgery
  • Non-Invasive Surgery
  • Combined Surgery

US Glaucoma Surgery Market Post-Operative Care Outlook

  • Follow-Up Procedures
  • Medication Management
  • Rehabilitation Services

US Glaucoma Surgery Market Patient Demographics Outlook

  • Age Group
  • Gender
  • Ethnicity
  • Socioeconomic Status

Report Scope

MARKET SIZE 2024178.67(USD Million)
MARKET SIZE 2025190.68(USD Million)
MARKET SIZE 2035365.4(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)6.72% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Million
Key Companies ProfiledAlcon (US), AbbVie (US), Johnson & Johnson (US), Bausch Health (US), Glaukos Corporation (US), Santen Pharmaceutical (US), Carl Zeiss AG (DE), Merck & Co. (US), Novartis (CH)
Segments CoveredSurgery Type, Procedure Type, Technology, Patient Demographics, Post-Operative Care
Key Market OpportunitiesAdoption of minimally invasive surgical techniques enhances patient outcomes in the US glaucoma surgery market.
Key Market DynamicsTechnological advancements and regulatory changes are reshaping the competitive landscape of the US glaucoma surgery market.
Countries CoveredUS

Leave a Comment

FAQs

What is the expected market size of the US Glaucoma Surgery Market in 2024?

The US Glaucoma Surgery Market is expected to be valued at 178.85 million USD in 2024.

What will be the projected market size of the US Glaucoma Surgery Market by 2035?

By 2035, the US Glaucoma Surgery Market is projected to reach 366.05 million USD.

What is the expected compound annual growth rate (CAGR) for the US Glaucoma Surgery Market from 2025 to 2035?

The expected CAGR for the US Glaucoma Surgery Market from 2025 to 2035 is 6.728%.

Which sub-segment of the US Glaucoma Surgery Market is expected to have the largest value in 2024?

The Trabecular meshwork sub-segment is expected to hold the largest value at 70.0 million USD in 2024.

What will be the market size for the Suprachoroidal space sub-segment by 2035?

The Suprachoroidal space sub-segment is expected to reach a market size of 120.0 million USD by 2035.

Who are the key players in the US Glaucoma Surgery Market?

Key players in the US Glaucoma Surgery Market include IRIDEX, Aerie Pharmaceuticals, Novartis, and Glaukos.

What is the expected value for the 'Others' sub-segment of the US Glaucoma Surgery Market in 2035?

'Others' sub-segment is projected to be valued at 96.05 million USD by 2035.

How does the US Glaucoma Surgery Market growth rate vary across regions?

The US Glaucoma Surgery Market is primarily driven by advancements in technology across the country.

What are some emerging trends in the US Glaucoma Surgery Market?

Emerging trends include increasing patient awareness and advancements in surgical techniques.

What challenges are currently facing the US Glaucoma Surgery Market?

Regulatory challenges and high treatment costs are significant challenges faced in the US Glaucoma Surgery Market.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓